SOURCE: IlluminOss Medical
EAST PROVIDENCE, RI--(Marketwired - Aug 27, 2013) - IlluminOss Medical, a privately held commercial stage medical device company in East Providence, Rhode Island, today announced that it has appointed industry veteran Dwayne Montgomery as its Senior Vice-President of Sales and Marketing. IlluminOss is pioneering the development of percutaneous, patient-customized orthopedic implants for the stabilization and treatment of bone fractures. Mr. Montgomery brings an extensive and proven track record of sales and marketing initiatives that make him an ideal fit to drive IlluminOss towards achieving its growth objectives in the fracture fixation market.
IlluminOss is uniquely positioned with a proprietary, disruptive technology that can significantly enhance how orthopedic fractures are treated. "Dwayne has an exceptional track record in orchestrating winning sales strategies for companies in some of the most competitive healthcare markets and has vast commercial experience centered on quickly developing strong surgeon relationships," said Dirk Kuyper, President & CEO of IlluminOss. "He is well respected by his colleagues for possessing exceptional business acumen. Dwayne is exactly the addition our well-rounded team needs to reach our sales goals as we move into the commercial ramp phase of the company."
Mr. Montgomery's career spans more than 20 years of building and leading successful medical device companies in large, mid-cap and venture-backed stages. Most recently, he served as Vice-President of Commercial Operations at TranS1, Inc. (now Baxano Surgical), where he was responsible for North American sales and sales operations. In addition to extensive marketing and sales experience, Mr. Montgomery was formerly the Global Vice President and General Manager for Smith & Nephew, Inc.'s Orthopedic Trauma Division. There he was responsible for global strategic direction and business management, including a $400M global sales business.
IlluminOss maintains CE Mark for clinical applications in light to low load bearing bones and is extending the platform technology to other extremities and applications. The company has direct distribution in Germany and is expanding in Europe with the recent addition of exclusive distribution in several key markets. The global bone fracture repair market was an estimated $5.5 billion in sales in 2010 and growing approximately 6% per annum, driven by population growth and aging populations around the globe.
"IlluminOss' product and procedure platform can revolutionize the approach and repair to patients suffering from traumatic, pathological, and osteoporotic bone fractures," said Dwayne. "The IlluminOss team is exceptional and I look forward to being a part of a company poised to significantly impact the industry. I believe there is a tremendous opportunity to advance the business and build substantial value by using the Photodynamic Bone Stabilization System delivering both high quality and cost-effective treatment for patients, providers and payers."
Mr. Montgomery holds a BS Degree in Chemistry from the University of North Alabama, an MBA from the Jack C. Massey School of Business at Belmont University and strategic marketing certificates from University of Michigan and University of Texas Schools of Business.
About IlluminOss Medical
IlluminOss Medical is a privately held commercial stage medical device company focused on designing, developing and marketing products that leverage its proprietary bone stabilization technology. IlluminOss Medical's proprietary Photodynamic Bone Stabilization System (PBSS) allows for fracture fixation through patient specific intramedullary implants. The PBSS System utilizes a light-curable polymer, contained within an expandable balloon catheter, to achieve bone stabilization. The revolutionary procedure is made through a small percutaneous surgical approach providing patients and clinicians with a fast, patient customized, method of orthopedic bone stabilization. The company currently markets its products in international countries under a CE Mark for approved clinical applications through both a direct sales force and distribution networks. Founded in 2007, IlluminOss is headquartered in East Providence, RI, and funded by Foundation Medical Partners, New Leaf Venture Partners, Tekla Capital, Life Sciences Partners, SR One, Longwood Fund, Excel Venture Management, Pappas Ventures, Mieza Capital, and Slater Technology Fund. Learn more at www.illuminoss.com.
The IlluminOss products are Investigational Devices; limited by Federal law to Investigational Use and are not approved for sale in the USA.